Previous 10 | Next 10 |
MaxCyte press release ( NASDAQ: MXCT ): Q2 GAAP EPS of -$0.08 in-line. Revenue of $9.6M (+35.2% Y/Y) beats by $0.37M . For further details see: MaxCyte GAAP EPS of -$0.08 in-line, revenue of $9.6M beats by $0.37M
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focu...
RGAIA Investment Advisors are an independent, fee-only investment management firm providing wealth management and financial planning for individuals, families, non-profit firms, and corporations of all sizes. Given any recession is bound to be of the traditional variety, there will no...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended June 30, 2022, Baron Health Care Fund declined 10.00% compared with the Benchmark. We are partic...
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, d...
MaxCyte ( NASDAQ: MXCT ) has announced the signing of a strategic platform license with LG Chem, aiming to create new value for its customers based on science. Under the terms, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electr...
GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, d...
BAMCO’s 13F portfolio value decreased from $47.14B to $40.75B this quarter. Ron Baron increased Spotify and Shopify while reducing Alphabet and Amazon.com. Their top five positions are at ~29% of the overall portfolio. For further details see: Tracking Ron Baron's...
Image source: The Motley Fool. MaxCyte, Inc. (NASDAQ: MXCT) Q1 2022 Earnings Call May 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: MaxCyte, Inc. (MXCT) Q1 2022 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2022 Earnings Conference Call May 9, 2022, 4:30 PM ET Company Participants Doug Doerfler – President and Chief Executive Officer Amanda Murphy – Chief Financial Officer Sean Menarguez – Investor Relations Conference Call Participants Stephanie Iann...
News, Short Squeeze, Breakout and More Instantly...
MaxCyte Inc. Company Name:
MXCT Stock Symbol:
NASDAQ Market:
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing...
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bio...
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc . , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and inn...